Claims in advertisements for antihypertensive drugs in a Dutch medical journal

Journal of Hypertension

Volumn 25, Issue 3, 2007, Pages 713-722

  Greving, Jacoba P ^a   Denig, Petra ^a   De Zeeuw, Dick ^a   Haaijer Ruskamp, Flora M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Advertising; Antihypertensive agents; Drug industry; Pharmaceutical promotion; Physicians

Indexed keywords

ACUZIDE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LERCANIDIPINE; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; MEPIRODIPINE; MIBEFRADIL; NIFEDIPINE; NITRENDIPINE; OLMESARTAN; PRAVASTATIN; QUINAPRIL; TELMISARTAN; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONSTIPATION; CORONARY ARTERY DISEASE; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; EDEMA; ENDOTHELIAL DYSFUNCTION; FLUSHING; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFORMATION; KIDNEY DISEASE; MEDICAL LITERATURE; PATIENT; POPULATION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 33846828565     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328012662a     Document Type: Article

References (29)

1. Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med 1992; 116:912-919.
2. Herxheimer A, Lundborg CS, Westerholm B. Advertisements for medicines in leading medical journals in 18 countries: a 12-month survey of information content and standards. Int J Health Serv 1993; 23:161-172.
3. Carandang ED, Moulds RF. Pharmaceutical advertisements in Australian medical publications - have they improved? Med J Aust 1994; 161:671-672.
4. Gutknecht DR. Evidence-based advertising? A survey of four major journals. J Am Board Fam Pract 2001; 14:197-200.
5. Loke TW, Koh FC, Ward JE. Pharmaceutical advertisement claims in Australian medical publications. Med J Aust 2002; 177:291-293.
6. Villanueva P, Peiro S, Librero J, Pereiro I. Accuracy of pharmaceutical advertisements in medical journals. Lancet 2003; 361:27-32.
7. Lankinen KS, Levola T, Marttinen K, Puumalainen I, Helin-Salmivaara A. Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals. Pharmacoepidemiol Drug Saf 2004; 13:789-795.
8. The Dutch Code of Conduct for pharmaceutical advertising. Gouda: CGR Foundation; 1998. Available at http://www.cgr.nl [accessed 24 November 2005].
9. European Code of Practice for the Promotion of Medicines. Geneva: International Federation of Pharmaceutical Industries and Associations; 1993. Available at http://www.efpia.org [accessed 24 November, 2005].
10. Jukema JW, Zwinderman AH, van Boven AJ, Reiber JH, Van der LA, Lie KI, et al. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler Thromb Vasc Biol 1996; 16:425-430.
11. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258-265.
12. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14:1237-1245.
13. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764.
14. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35:60-66.
15. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
16. Oosterga M, Anthonio RL, de Kam PJ, Kingma JH, Crijns HJ, van Gilst WH. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol 1998; 81: 1178-1181.
17. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
18. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
19. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
20. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
21. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
22. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
23. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982; 73:4-8.
24. Levy R. The role and value of pharmaceutical marketing. Arch Fam Med 1994; 3:327-332.
25. Freemantle N. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? BMJ 2005; 331:836-838.
26. Lexchin J. Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines? Can Med Assoc J 1997; 156:351-356.
27. Kmietowicz Z. NHS criticised for lax control over drugs industry. BMJ 2005; 330:805.
28. Gerritsen H, van der Meij A, Mosmans M, Oonk M, Piepenbrink J, van der Vliet C, et al. Monitoring pharmaceutical care. Diemen: Health Care Insurance Board; 2003.
29. EMEA. Note for guidance on clinical investigation on medicinal products in the treatment of hypertension. London: EMEA; 1997. Available at http://www.emea.eu.int [accessed 27 January 2006].